Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-403, glucokinase activator · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-403 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ARRY-403, glucokinase activator; oral | DRUG | multiple dose, escalating |
| Placebo; oral | DRUG | matching placebo |
Key Inclusion Criteria: * Male or female (females must be of non-childbearing potential), between the ages of 18 and 70 years, inclusive. * Diagnosis of Type 2 diabetes. * Fasted C-peptide value ≥ 0.8 ng/mL. * HbA1c ≥ 6.5% and ≤ 10.0% for monotherapy cohorts (study drug only) or HbA1c ≥ 7.5% and ≤ ...
Top 20 of 31 competitors
ARRY-403 is an investigational small molecule being developed for the treatment of Type 2 Diabetes. It is a glucokinase activator, a class of drugs that targets the enzyme glucokinase to help regulate blood sugar levels. The drug is currently in Phase 1 clinical development.
ARRY-403 targets glucokinase, an enzyme that plays a key role in glucose sensing and metabolism. By activating glucokinase, the drug aims to enhance glucose uptake and insulin secretion, which may help control blood sugar in patients with Type 2 Diabetes.
ARRY-403 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical trials for Type 2 Diabetes.
ARRY-403 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, both focusing on safety in patients with Type 2 Diabetes.
ARRY-403 has been studied in two completed Phase 1 clinical trials: NCT00859755 and NCT00952198. Both were safety studies in patients with Type 2 Diabetes, conducted in the United States, with a combined enrollment of 169 participants.
Yes, ARRY-403 is a glucokinase activator. This means it works by activating the glucokinase enzyme, which is involved in glucose metabolism. This mechanism is being investigated for its potential to treat Type 2 Diabetes.